Janux Therapeutics (JANX) Analyst & Key Data

Analyst Consensus

Buy14 analysts

Buy

Updated Sep 12, 2026

Total Analysts14

Buy

12

Hold

3

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score1.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$17.10

Median Target+97.13%

$33.71

Potential upside vs current price

DCF Value-117.31%

-$2.96

Potential downside vs current price

Current Stock Price

$17.10

Median Target+97.13%

$33.71

Potential upside vs current price

DCF Value-117.31%

-$2.96

Potential downside vs current price

Analyst Consensus

Buy14 analysts

Buy

Updated Sep 12, 2026

Total Analysts14

Buy

12

Hold

3

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score1.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$17.10

Median Target+97.13%

$33.71

Potential upside vs current price

DCF Value-117.31%

-$2.96

Potential downside vs current price

Current Stock Price

$17.10

Median Target+97.13%

$33.71

Potential upside vs current price

DCF Value-117.31%

-$2.96

Potential downside vs current price

Janux Therapeutics, Inc.